Lupus nephritis in children: A longitudinal study of prognostic factors and therapy

Journal of the American Society of Nephrology

Volumn 7, Issue 6, 1996, Pages 924-929

  Baqi, Noosha ^a   Moazami, Shohreh ^a   Singh, Anup ^a   Ahmad, Hadi ^a   Balachandra, Shivaiha ^a   Tejani, Amir ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Disease progression; Prognosis; Renal failure; Systemic lupus erythematosus; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK FACTOR;

EID: 0030372748     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hargraves MM, Richmond H, Morton R: Presentation of two bone marrow elements. The "tart" cell and the L.E. cell. Proc Staff Meet Mayo Clin 1948;23:25-28.
2. Coggins CH: Overview of treatment of lupus nephritis. Am J Kidney Dis 1982;2:197-200.
3. Pollack VE, Dosekun AK: Evaluation of treatment in lupus nephritis. Am J Kidney Dis 1982;2[Suppl 1]:170-177.
4. Balow JE, Austin HA III, Tsokas GC, Antonovych TT, Steinberg AD, Klippel JH: Lupus nephritis. Ann Intern Med 1987;106:79-94.
5. Revielle JD, Bartolucci A, Alarcon GS: Prognosis in systemic lupus erythematosus. Arthritis Rheum 1990; 33:37-48.
6. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL: Cyclophosphamide in lupus nephritis: Acontrolled trial. Ann Intern Med 1971;75:165-171.
7. Carette S, Klippel JH, Decker JL, et al.: Controlled studies of oral imnumosuppressive drugs in lupus nephritis: A long term follow-up. Ann Intern Med 1983;99: 1-8.
8. Plotz PH, Klippel JH, Decker JL, et al.: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979;91:221-223.
9. Bacon AM, Rosenberg SA: Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982;97:62-63.
10. Tannenbaum H, Schur PH: Development of reticulum cell sarcoma during cyclophosphamide therapy. Arthritis Rheum 1974;17:15-18.
11. Balow JE, Austin HA, Muenz LR, et al.: Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-495.
12. Austin HA, Klippel JH, Balow JE, et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
13. Patience H, White MD: Pediatric systemic lupus and erythematosus and neonatal lupus. Rheum Dis Clin North Am 1994;20:119-127.
14. McCune WJ, Golbus J, Zeldes W, et al.: Clinical and immunologie effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-1431.
15. Valeri A, Radhakrishnan J, Estes D, et al.: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study. Clin Nephrol 1994; 42:71-78.
16. Magill AB, Puterman ML, Ballon HS, et al.: Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988;34:511-517.
17. Seleznick MJ, Fries JF: Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991;21:73-80.
18. Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcome in severe lupus nephritis: Contributions of clinical and histological data. Kidney Int 1994;45:544-550.
19. Studenski S, Allen NB, Caldwell DS, et al.: Survival in systemic lupus erythematosus: A multivariate analysis of demographic factors. Arthritis Rheum 1987;30:1326-1332.
20. Lehman TJA, Sherry DD, Wagner-Weiner L, et al.: Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989;114:1055-1060.
21. McCurdy DK, Lehman TJA, Bernstein B, et al.: Lupus nephritis: Prognostic factors in children. Pediatrics 1992;89:240-246.
22. Tejani A, Nicastri AD, Chen CK, Fikrig S: Gurumurthy kunchitapatham: Lupus nephritis in Black and Hispanic children. Am J Dis Child 1983;137:481-483.
23. Tan EM, Cohen AS, Fries JF, et al.: The 1982 Revised Criteria For the Classification of Systemic Lupus Erythematosus. Arthritis Rheum 1982;25:1271-1277.
24. Schwarte GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571-590.
25. Hosmer DW Jr, Lemeshow S: Applied Logistic Regression. New York: John Wiley and Sons; 1989.
26. Norusis MJ: SPSS/PC+ (Statistical Package for the Social Sciences). [MS-DOS version.] Chicago: SPSS Inc.; 1988.
27. Meislin AG, Rothfield N: Systemic lupus erythematosus in childhood - Analysis of 42 cases with comparitive data on 200 adult cases followed concurrently. Pediatrics 1968;42:37-45.
28. Walravens PA, Chase HP: The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 1976; 130:929-933.
29. Lehman TJA: Long-term outcome of systemic lupus erythematosus in childhood. Rheum Dis Clin North Am 1991;17:921-930.
30. Fish AJ, Blau EB, Westberg NG, et al.: Systemic lupus erythematosus within the first two decades of life. Am J Med 1977;62:99-117.
31. Garin EH, Donelly WH, Fennell RS, et al.: Nephritis in systemic lupus erythematosus in children. J Pediatr 1976;89:366-371.
32. Ginzler EM, Diamond HS, Weiner M, et al.: A multicenter study of outcome in systemic lupus erythematosus. Arthritis Rheum 1982;25:601-611.
33. Austin HA, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-1628.
34. Dubois EL, Wierzchowiecki M, Cox MB, et al.: Duration and death in systemic lupus erythematosus: An analysis of 249 cases. JAMA 1974;227:1399-1402.
35. Wallace DJ, Podell T, Weiner J, et al.: Systemic lupus erythematosus-survival patterns: Experience with 609 patients. JAMA 1981;245:934-938.
36. Whiting-O'Keefe Q, Henke JE, Shearn MA, et al.: The information content from renal biopsy in systemic lupus erythematosus: Step-wise linear regression analysis. Ann Intern Med 1982;96:718-723.
37. Esdaille JM, Federgreen W, Quintal H, et al.: Predictors of one year outcome in lupus nephritis: The importance of renal biopsy. Q J Med 1991;81:907-918.
38. McLaughlin J, Gladman DD, Urowitz MB, et al.: Kidney biopsy in systemic lupus erythematosus. II Survival analysis according to biopsy results. Arthritis Rheum 1991;34:1268-1273.
39. Boumpas DT, Austin HA, Vaughn EM, et al.: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-369.
40. Dinant HJ, Decker JL, Klippel HJ, Balow JE, Plotz PH, Steinberg AD: Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982;96:728-736.
41. Ostrov BE, Min W, Eichenfield AH, et al.: Hypertension in children with systemic lupus erythematosus. Semin Arthritis Rheum 1989;19:90-98.
42. Austin HA, Balow JE: Henoch-Schonlein nephritis: Prognostic features and challenge of treatment. Am J Kidney Dis 1983;2:512-520.
43. Morgensen CE: Long-term anti-hypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982;285:685-688.
44. Yang LY, Chen WP, Lin CY: Lupus nephritis in children - A review of 167 patients. Pediatrics 1994;94:335-340.